文献速递瓣膜外科

COMMENCE试验五年结果:RESILIA组织主动脉瓣置换研究

Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement With RESILIA Tissue.
PubMed 文献 · Ann Thorac Surg · 2022-01-20

COMMENCE试验为前瞻性、多国、多中心(27家)FDA IDE研究,2013年1月至2016年3月纳入689例患者行RESILIA组织牛心包生物瓣主动脉瓣置换。5年随访显示全因死亡率 actuarial 89.2%,结构性瓣膜退化100%免于发生,全因再干预98.7%免于发生。

要点

  • 5年结构性瓣膜退化免于发生率为100%,无证据显示结构性瓣膜退化。
  • 5年全因死亡率 actuarial 免于发生率为89.2%,全因再干预免于发生率为98.7%。
  • 5年时97.8%患者心功能I/II级,有效瓣口面积1.6±0.5 cm2,平均压差11.5±6.0 mm Hg。

核心结论

  • 该RESILIA组织主动脉生物瓣5年安全性和血流动力学表现令人鼓舞,血流动力学临床稳定、反流极少,无结构性瓣膜退化证据。

研究设计与样本

  • 前瞻性、多国、多中心(n=27)、美国食品药品监督管理局研究性器械豁免试验,评估RESILIA组织牛心包生物瓣(model 11000A)主动脉瓣置换。
  • 2013年1月至2016年3月共689例患者接受研究瓣膜,平均年龄66.9±11.6岁,STS预测死亡风险2.0%±1.8%。
  • 事件由独立临床事件委员会裁定,超声心动图由独立核心实验室分析,报告观察期5年结果。

主要发现

  • 截至2020年12月11日,随访时长4.3±1.4年,观察期随访完整度95.5%。
  • 早期(<30天)全因死亡率1.2%,卒中1.6%,重大瓣周漏0.1%。
  • 5年 actuarial 全因死亡免于发生率89.2%,结构性瓣膜退化免于发生率100%,全因再干预免于发生率98.7%。
  • 5年时有效瓣口面积1.6±0.5 cm2,平均压差11.5±6.0 mm Hg,97.8%患者为I/II级,97.8%和96.3%患者无/微量瓣周和跨瓣反流。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COMMENCE trial was conducted to evaluate the safety and effectiveness of aortic valve replacement using a bioprosthesis with novel RESILIA tissue (Edwards Lifesciences). RESILIA tissue is incorporated in the INSPIRIS RESILIA aortic valve (Edwards Lifesciences). METHODS: Patients underwent clinically indicated surgical aortic valve replacement with a bovine pericardial bioprosthesis (model 11000A; Edwards Lifesciences) in a prospective, multinational, multicenter (n = 27), US Food and Drug Administration Investigational Device Exemption trial. Events were adjudicated by an independent clinical events committee, and echocardiograms were analyzed by an independent core laboratory. Outcomes through an observational period of 5 years are reported. RESULTS: Between January 2013 and March 2016, 689 patients received the study valve. Mean patient age was 66.9 ± 11.6 years; Society of Thoracic Surgeons Predicted Risk of Mortality was 2.0% ± 1.8%; and 23.8%, 49.9%, and 24.4% of patients were New York Heart Association functional class I, II, and III at baseline, respectively. Through December 11, 2020 the follow-up duration was 4.3 ± 1.4 years, and the completeness of follow-up over the observational period was 95.5%. Early (<30 days) all-cause mortality was 1.2%, stroke 1.6%, and major paravalvular leak 0.1%. Five-year actuarial freedom from all-cause mortality, structural valve deterioration, and all-cause reintervention were 89.2%, 100%, and 98.7%, respectively. At 5 years the effective orifice area was 1.6 ± 0.5 cm2, mean gradient was 11.5 ± 6.0 mm Hg, 97.8% of patients were class I/II, and 97.8% and 96.3% of patients had none/trace paravalvular and transvalvular regurgitation, respectively. CONCLUSIONS: The safety and hemodynamic performance of this aortic bioprosthesis with RESILIA tissue through 5 years are encouraging, with clinically stable hemodynamics, minimal regurgitation, and no evidence of structural valve deterioration.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bavaria JE, Griffith B, Heimansohn DA, et al. Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement With RESILIA Tissue. Ann Thorac Surg. 2022. PMID: 35065065. doi:10.1016/j.athoracsur.2021.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。